Recent Finacing
Recent Raise
NormOxys develops small-molecule therapeutics and a proprietary oxyren platform to enhance oxygen delivery to hypoxic tissues; lead candidate OXY111A has FDA IND clearance for oncology and heart failure.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors